Seoul, South Korea

Won Ii Yoo

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Eyegene Inc.. Active years: 2017.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Won Ii Yoo

Introduction

Won Ii Yoo is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in vaccine development. His work focuses on enhancing immune responses through innovative vaccine compositions.

Latest Patents

Won Ii Yoo holds a patent for a vaccine designed to induce an improved immune reaction. This pharmaceutical vaccine composition includes a pathogen-derived antigen selected from various viruses, such as hepatitis A, hepatitis B, hepatitis C, human immunodeficiency virus, influenza, herpes simplex virus, and varicella virus. Additionally, the composition features a deacylated non-toxic lipooligosaccharide and a pharmaceutically acceptable carrier. This patent highlights his commitment to advancing medical science and improving public health.

Career Highlights

Throughout his career, Won Ii Yoo has been associated with Eyegene Inc., a company dedicated to innovative solutions in biotechnology. His work at Eyegene has allowed him to collaborate with other talented professionals in the field, contributing to groundbreaking research and development.

Collaborations

Some of his notable coworkers include Kwang Sung Kim and Yang Je Cho. Their collective efforts have fostered an environment of innovation and creativity, leading to advancements in vaccine technology.

Conclusion

Won Ii Yoo's contributions to vaccine development exemplify the impact of innovative thinking in the pharmaceutical industry. His patent for an improved vaccine composition showcases his dedication to enhancing immune responses and improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…